Featured
Economical Preclinical PK Immunoassay
A start-up biotechnology company developed a library of constructs having the Fc portion of human IgG and their warhead denoted as X for confidential reasons. Fc-X fusion protein drug candidates were distinguished by amino acid substitutions in the warhead moiety, changes that were predicted to affect PK characteristics.
